Quantcast

Latest Morpholines Stories

2014-07-17 23:04:20

Zoll, Kranz & Borgess, LLC, (ZKB), an experienced pharmaceutical and medical device litigation firm, is currently investigating claims of individuals who developed bleeding, clotting or other serious side effects or even death after taking the pharmaceutical drug, Xarelto® (rivaroxaban). Toledo, OH (PRWEB) July 17, 2014 Xarelto® (rivaroxaban) is an anticoagulant marketed in the U.S. by Janssen Pharmaceutical, a subsidiary of Johnson & Johnson. It is used to prevent blood...

2014-06-25 23:11:26

Several Xarelto users are considering filing a Xarelto lawsuit after suffering dangerous side effects associated with the popular blood thinner drug Xarelto (rivaroxaban). The Levin, Papantonio law firm has launched a Xarelto lawsuit website to assist those who have been injured from severe internal bleeding experienced after taking the blood thinner drug. Pensacola, FL (PRWEB) June 25, 2014 Users of the prescription drug Xarelto (rivaroxaban) are beginning to file Xarelto lawsuits after...

2014-06-10 12:29:47

Additional Novel Oral Anticoagulants are Expected to Gain Approval in China for AF and VTE in the Next Three to Four Years, According to Findings from Decision Resources Group BURLINGTON, Mass., June 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs) in the Chinese market. Warfarin, the mainstay of anticoagulation treatment, is listed in the national essential drugs list and is...

2014-05-28 08:30:57

SAN DIEGO, May 28, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ:AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Jefferies 2014 Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on June 2-5, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate,...

2014-05-19 23:11:24

Reliable Biopharmaceutical Corporation (RBC) announces the launch of cGMP MES Buffer. As regulations surrounding supply chain and excipient quality become more stringent, there is a need for high quality GMP commercial ingredient manufacturing. St. Louis, MO (PRWEB) May 19, 2014 cGMP MES Buffer is used in many critical processes by the biopharmaceutical industry. As regulations surrounding supply chain and excipient quality become more stringent, there is a need for high quality GMP...

2014-05-14 23:14:48

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. Chicago, IL (PRWEB) May 14, 2014 The drug safety advocates at DrugNews.net are alerting patients who have taken the anticoagulant Xarelto of new information on the site. A new report warns that the number of internal bleeding cases linked to the drug is steadily rising*. DrugNews is a free resource providing the latest product recalls, safety...

2014-05-06 16:33:03

Quizartinib QUANTUM-R Phase 3 Trial Begins SAN DIEGO, May 6, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the first quarter 2014. The company will host a conference call today to discuss financial results for the first quarter, and to provide an update on plans and activities for 2014. "We...

2014-05-01 08:35:41

SAN DIEGO, Calif., May 1, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Deutsche Bank 39(th) Annual Healthcare Conference to be held at the InterContinental Hotel in Boston, MA, May 7-8, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug...

2014-04-22 08:32:37

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report first quarter operational results after closing of the NASDAQ Global Market on Tuesday, May 6, 2014. A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the same...

2014-03-31 08:29:45

RARITAN, N.J., March 31, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO(®) (rivaroxaban), the most studied and broadly indicated oral Factor Xa inhibitor in the world today. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related